Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vical presents Leuvectin and Allovectin data

Interim data from 37 of 61 patients in VICL's Phase II trial of Leuvectin showed that tumor burden was reduced in

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE